GLP1R and type 2 diabetes mellitus: Interestingly, glucagon-like-peptide-1-based (GLP-1-based) antidiabetic therapy protects from AAA formation in animal models [6], suggesting a role for GLP-1 in the reduced prevalence of AA in T2D.